Basit öğe kaydını göster

Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents

dc.contributor.authorOzguroglu, Mustafa
dc.contributor.authorDELANOY, Nicolas
dc.contributor.authorBELLMUNT, Joaquim
dc.contributor.authorOUDARD, Stephane
dc.contributor.authorANGELERGUES, Antoine
dc.contributor.authorEFSTATHIOU, Eleni
dc.contributor.authorGYFTAKI, Revekka
dc.contributor.authorWYSOCKI, Piotr Jan
dc.contributor.authorLAINEZ, Nuria
dc.contributor.authorGONZALEZ, Iria
dc.contributor.authorCASTELLANO, Daniel E.
dc.contributor.authorGARCIA CARBONERO, Iciar
dc.contributor.authorFLECHON, Aude
dc.contributor.authorBORREGA, Pablo
dc.contributor.authorGUILLOT, Aline
dc.contributor.authorCAMPOS BALEA, Begona
dc.contributor.authorLE MOULEC, Sylvestre
dc.contributor.authorESTEBAN, Emilio
dc.contributor.authorMUNARRIZ, Javier
dc.contributor.authorRUBIO, Gustavo
dc.contributor.authorBIRTLE, Alison J.
dc.date.accessioned2021-03-02T22:24:27Z
dc.date.available2021-03-02T22:24:27Z
dc.date.issued2018
dc.identifier.citationANGELERGUES A., EFSTATHIOU E., GYFTAKI R., WYSOCKI P. J. , LAINEZ N., GONZALEZ I., CASTELLANO D. E. , Ozguroglu M., GARCIA CARBONERO I., FLECHON A., et al., "Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents", CLINICAL GENITOURINARY CANCER, cilt.16, sa.4, 2018
dc.identifier.issn1558-7673
dc.identifier.otherav_0c779b22-45b8-4270-ad53-883720639106
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/14029
dc.identifier.urihttps://doi.org/10.1016/j.clgc.2018.02.016
dc.description.abstractSeveral agents have demonstrated an overall survival (OS) benefit in metastatic castration-resistant prostate cancer (mCRPC); however, optimal sequencing is unknown. Retrospective analysis of data from 574 mCRPC patients showed increasing OS with the number of therapies provided; a sequence including docetaxel, cabazitaxel (CABA), and an androgen receptor-targeted agent (ART) provided the greatest benefit. Prior administration of ART did not appear to influence CABA activity. These findings will help guide treatment decisions in daily practice.
dc.language.isoeng
dc.subjectTıp
dc.subjectOnkoloji
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectÜROLOJİ VE NEFROLOJİ
dc.subjectNefroloji
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.titleResults of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents
dc.typeMakale
dc.relation.journalCLINICAL GENITOURINARY CANCER
dc.contributor.department, ,
dc.identifier.volume16
dc.identifier.issue4
dc.contributor.firstauthorID44333


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster